Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies.
van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, van Gent DC, Hardillo J, Verduijn GM, Drooger JC, van Rhoon GC, Smedts DHPM, van Doorn HC, Boormans JL, Jager A, Franckena M, Kanaar R.
van den Tempel N, et al. Among authors: van holthe n, van gent dc, van doorn hc, van rhoon gc.
Int J Hyperthermia. 2018 Jun;34(4):407-414. doi: 10.1080/02656736.2017.1355487. Epub 2017 Jul 31.
Int J Hyperthermia. 2018.
PMID: 28705099
Free article.